A Phase I/II, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7787 in Patients With Advanced Solid Tumors
Latest Information Update: 01 Oct 2024
At a glance
- Drugs SHR 7787 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Hengrui Pharmaceutical
- 01 Oct 2024 New trial record